The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment

Abstract

Clinical outcome assessment in Multiple Sclerosis (MS) is challenging due to the diversity and fluctuating nature of MS symptoms. Traditional clinical scales such as the EDSS are inadequate in their assessment of key clinical dimensions of MS (e.g., cognitive function), and they have psychometric limitations as well. Based on analyses of pooled data from natural history studies and from placebo groups in clinical trials, the National MS Society's Clinical Outcomes Assessment Task Force recently proposed a new multidimensional clinical outcome measure, the MS Functional Composite (MSFC). The MSFC comprises quantitative functional measures of three key clinical dimensions of MS: leg function/ambulation, arm/hand function, and cognitive function. Scores on component measures are converted to standard scores (z-scores), which are averaged to form a single MSFC score. Preliminary analyses confirm that: (1) the three clinical dimensions of the MSFC are relatively independent; (2) the MSFC is sensitive to clinical changes over 1- and 2-year intervals; and (3) the MSFC has acceptable criterion validity (i.e., predicts both concurrent and subsequent EDSS change). The advantages and potential limitations of incorporating quantitative functional outcome measures such as the MSFC into collaborative databases are discussed.

Keywords

multiple sclerosis clinical trials clinical outcome assessment MS Functional Composite (MSFC)

Get full access to this article

View all access options for this article.

References

Kurtzke JF. (1983) Rating neurologic impairment in multiple sclerosis; An expanded disability status scale (EDSS) . Neurology 33: 1444-1452 .

Whitaker JN , McFarland HF , Rudge P , Reingold SC. (1995) Outcomes assessment in multiple sclerosis clinical trials: a critical analysis . Multiple Sclerosis 1: 37-47 .

Sipe JC et al. (1984) A neurologic rating scale (NRS) for use in multiple sclerosis . Neurology 34: 1368-1372 .

Cook SD et al. (1986) Effect of total lymphoid irradiation in chronic progressive multiple sclerosis . Lancet 1: 1405-1409 .

Ravnborg M , Grùnberg-Jensen M , Jonsson A. (1997) The MS impairment scale: a pragmatic approach to the assessment of impairment in patients with multiple sclerosis . Multiple Sclerosis 3: 31-42 .

Potvin AR , Tourtellotte WW. (1985) Quantitative examination of neurologic function. Vol II. Methodology for test and patient assessments and design of a computer-automated system. Boca Rator, FL: CRC Press .

Rudick RA et al. (1996) Clinical outcomes assessment in multiple sclerosis . Ann Neurol 40: 469-479 .

Syndulko K et al. (1996) Comparative evaluations of neuroperformance and clinical outcome assessments in multiple sclerosis. I. Primary dimensions, construct validation and sensitivity to disease progression . Multiple Sclerosis 2: 142-156 .

Petkau AJ. (1996) Statistical and design considerations for multiple sclerosis clinical trials. In Goodkin DE , Rudick RA (eds.), Multiple sclerosis: advances in clinical trial design, treatment, and future perspectives. London: Springer pp 63-103.

10.

Goldsmith CH , Smythe HA , Helawa A. (1993) Interpretation and power of a pooled index . J Rheumatol 20: 575-578 .

11.

Rudick RA et al. (1997) Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force . Ann Neurol 42: 379-382 .

12.

Ellison GW et al. (1989) A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis . Neurology 39: 1018-1026 .

13.

The Multiple Sclerosis Study Group . (1990) Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial . Ann Neurol 27: 591-605 .

14.

Goodkin DE et al. (1995) Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis . Ann Neurol 37: 30-40 .

15.

Jacobs LD et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis . Ann Neurol 39: 285-294 .

16.

Cutter GR et al. (1999) Development of a Multiple Sclerosis Functional Composite as a clinical trial outcome measure . Brain 122: 87-88 .

17.

Fischer JS et al. (1999). Administration and scoring manual for the MS Functional Composite measure (MSFC). New York: Demos .

18.

Schwid SR et al. (1997) The measurement of ambulatory impairment in multiple sclerosis . Neurology 49: 1419-1424 .

19.

Goodkin D , Hertsgaard D , Seminary J. (1988) Upper extremity function in multiple sclerosis: improving assessment sensitivity with Box-and-Block and 9-Hole Peg Tests . Arch Phys Med Rehabil 69: 850-854 .

20.

Gronwall D. (1977) Paced auditory serial addition task: a measure of recovery from concussion . Percept Mot Skills 44: 363-373 .

21.

Rao S et al. (1989) Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis . Neurology 39: 161-166 .

22.

Fischer JS et al. Intra- and inter-rater reliability of the Multiple Sclerosis Functional Composite . Neurology 52: A50-A50 .

23.

Bever CT , Grattan L , Panitch HS , Johnson KP. (1995) The brief repeatable battery of neuropsychological tests for multiple sclerosis: a preliminary serial study . Multiple Sclerosis 1: 165-169 .

24.

Syndulko K et al. (1993) Neuroperformance evaluation of multiple sclerosis disease progression in a clinical trial: implications for neurological outcomes . J Neuro Rehab 7: 153-176 .

25.

Brooks BR et al. (1994) The natural history of amyotrophic lateral sclerosis. In AC Williams (ed.) Motor neuron disease. New York: Chapman & Hall Medical pp 131-169.